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data on the general population. Specific examples of large systematic reviews con-
ducted for estimating food safety accounting for population variability and inter-
actions between food contaminants and drugs are also presented. Details on the 
model-based meta-analyses of such safety data are described and discussed for the 
purpose of regulator’s decision making. Systematic reviews have been to the context 
of food and nutritional epidemiology requiring more stringent quality assessment 
and more advanced management of variability. This resulted in a Bayesian random 
effect model accounting for population variability. Metabolic interactions between 
food and drugs were evidenced and variability metrics could be explicated in terms of 
“uncertainty factors” to be used by the food regulators to assess safety limits for food 
ingredients, contaminants or drugs and their combined use. Food regulator in EU is 
aligning and even sometimes anticipating drug regulators in terms of evidence-based 
safety assessment in the real life. Common tools for model-based evidence synthesis 
can be applied to quantify safety signals and interaction in the general population.
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Objectives: Cost-effectiveness analyses (CEA) have become widely used in several 
pathologies. Currently, new CEA studies comparing active vs control treatment have 
been incorporated each year. For this reason, the combination of CEA studies could 
give a more consistent and accurate estimate of an intervention’s efficiency than 
one study alone. The aim of study was to develop a new method to do compara-
tive efficiency research (COMER) based in individual patient data. MethOds: After, 
adjusted the marginal distribution and copula distribution of a hypothetical cohort, 
we stated the parameters and distribution estimated like our unknown theoretical 
distribution. We conducted an iterative analysis of a random Frank Copula distribu-
tion with a different range of sample size. We performed a comparison between 
samples and theoretical distribution in terms of incremental cost-effectiveness ratio 
(ICER), incremental monetary benefit(IMB) fixed a threshold (k= 20.000 monetary 
units) and goodness of fit for Frank copula, assuming a tolerance. Results: The 
Theoretical distribution fixed, showed a cost of 604.34 monetary units for active and 
516.12 monetary units for control, and a utilities of 0.529 for active and 0.492 for 
control. ICER for theoretical cohort was 2,380 monetary units per quality-adjusted 
life year gained and IMB was 653. With a tolerance of 500 monetary units for ICER 
and 50 monetary units for IMB, only 15.52% of simulations were near the theoretical 
ICER and only 6.12% of IMB. The amount of individual patients simulated was more 
than 500 patients per treatment to fit Frank Copula. cOnclusiOns: Preliminary 
results showed that COMER based in individual patients’ data could allow decision 
maker to know real add-value of a new intervention.
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Benefits of diagnostics tests generally centre on test accuracy measures. However, 
additional benefits of diagnostics may include: reduced laboratory time, reduced time 
to results and increases in the capacity of a laboratory to deliver more tests. New tech-
nological developments, such as high throughput sequencing (HTS) are challenging the 
current methods used in establishing the case for the introduction into clinical practice 
terms of economic impact. This is evident in the case study developed here examining 
BRCA1/2 genetic testing in providing information on the risk of development of breast 
cancer. Current BRCA1/2 testing technologies are limited by long (up to one-year) turna-
round times, which together with limited resources to increase the volume of tests 
and associated genetic counselling, has driven the use of a ‘risk threshold’ to target 
women eligible for testing. HTS offers the opportunity of decreased turnaround time 
and increased volume of BRCA1/2 tests, which will impact on the benefits and costs 
associated with the diagnostic service. Systematic reviews have identified Markov-type 
models as the dominant modeling methodology for the assessment of genetic testing. 
We propose that discrete event simulation (DES) is the appropriate model type to quan-
tify the economic impact of HTS BRCA1/2 testing as it allows evaluation of the impact 
of capacity constraints and increased turnaround time on the costs and benefits of 
this new diagnostic technology. Importantly, DES also allows for the assessment of 
structural uncertainty by considering changes in patient pathways when using a new 
diagnostic technology. While DES may be the most appropriate modeling methodology 
in assessing the economic impact of novel genetic tests; typically the type of data and 
information required to popuate these models in lacking. We conclude by highlighting 
the type of data required to both population appropriate models and to adequately 
assess the economic impact of these novel genetic tests.
PRM242
the iMPoRtanCe of sensitivity analyses in health teChnology 
assessMents
Hren R.
University of Ljubljana, Ljubljana, Slovenia
In this paper, we critically evaulated analytical design of health technology assess-
ment methodologies, particularly related to sensitivity analyses and willingness-
to-pay thresholds. To this end, we have used two studies: the first one analyzing 
cost-effectiveness of a human papillomavirus vaccination of boys at age 12 against 
oropharyngeal carcinoma and anogenital warts and the second one examining 
cost-effectiveness of a universal programme of vaccinating children against pneu-
mococcal disease. We have shown – as expected – that the impact of variation of 
parameters can be substantial, however, outcomes of sensitivity analyses are often 
understated both by marketing authorization holders and authorities. Few would 
of a biopharmaceutical company. An approach based on real options valuation 
model was proposed to support investment and market decisions and to predict the 
potential net present value (NPV) of a drug. The conceptual structure of the model 
was face-validated by health economic and valuation experts. Results: A deci-
sion-tree based valuation method, populated partially by information from health 
economic tools, was adopted to analyse and clearly communicate R&D investment 
opportunities, to capture management flexibility and to improve strategic thinking. 
A feedback loop can be built into the model to analyse resiliency to assumption 
changes. In early phases, headroom and multi-criteria decision analyses indicate 
the likelihood of an investment being cost-effective. Phase I and II trials provide 
early evidence on drug efficacy and tolerability and initial cost estimates. Based 
on value of information, cost-effectiveness and budget impact models, only drugs 
deemed to meet authority requirements would be selected. Market intelligence 
and uncertainties and clinical success probability further enable identification of 
the optimal portfolio containing drug candidates that maximize NPV for given risk 
levels. cOnclusiOns: Health economic methods are commonly applied during 
late stage development, but if implemented alongside capital investment tools from 
earliest R&D stages they could increase the likelihood of selecting the right products 
to compose an effective investment portfolio.
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Cancer treatment effectiveness is often quantified by analyzing time from treat-
ment initiation to the occurrence of a particular event. Very commonly studies 
report data on overall survival (OS), where the event is death from any cause, and on 
progression-free survival (PFS), where the event is death from any cause or disease 
progression, whichever occurred first. Both OS and PFS can inform decision making. 
Separate meta-analyses of OS and of PFS data ignore the correlation between the 
outcomes. We introduce a method for the joint meta-analysis of OS and PFS that is 
based on a tri-state transition model with time-varying hazard rates modeled with 
fractional polynomials. In English, we assume that, at any time, patients can be in 
one of three health states: “alive but not progressed”, “alive and progressed”, and 
“dead”. PFS corresponds to time spent in the first state, and OS to time spent in the 
two alive states. The proposed approach allows the joint network meta-analysis 
of OS and PFS, relaxes the proportional hazards assumption, extends to a network 
of more than two treatments, and simplifies the parameterization of decision and 
cost-effectiveness analyses. The data needed to run these analyses can be extracted 
directly from published survival curves. We demonstrate use by applying the meth-
odology to a network of trials for the treatment of non-small cell lung cancer.
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bAckgROund: The global economic crisis imposes severe restrictions on budgets 
allocated to health care. Innovative technologies in medicine may improve patient 
outcomes but such improvements come at a substantial cost, thus limiting the num-
ber of patients that may benefit from them. According to current cost-effectiveness 
analyses (CEA), most innovative interventions are associated with a higher efficacy 
and higher costs compared with the standard of care. These analyses do not account 
for the budget impact associated with implementing the interventions on all eligible 
patients. Even when a new intervention is highly cost-effective, health care systems 
may not be able to adopt it due to substantial budgetary impacts. Implementing a 
substantially lower-cost intervention to a substantially wider population, accept-
ing inferior per-patient outcomes, may improve overall health outcomes under a 
restricted budget. Objectives: Develop an innovative health technology assess-
ment (HTA) model that combines CEA and budget-impact analyses, thus enabling to 
compare the impact of intervention alternatives on the entire intended use popula-
tion, under a pre-specified budget constraint. MethOds: We identified the follow-
ing steps to be included in the model formulation: 1) Define the intended use and the 
target population. 2) Define two or more interventions, one of them at higher cost 
and better per-patient outcome, and the second with lower cost and inferior per-
patient outcome. 3) Forecast the diffusion of the alternatives into the entire intended 
use population, under a pre-defined budget, in order to estimate the treated and 
untreated populations. 4) Calculate the clinical impact of each alternative on the 
treated population. 5) Calculate the clinical impact of no therapy on the untreated 
population 6) Compare the aggregated clinical impact of each alternative on the 
entire intended use population – both treated and untreated. Using the proposed 
population-based model may result in improved health care outcomes, especially 
in times of economic downturn and austerity.
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Evidence-based medicine has emerged as the bottom line of Health Technology 
Assessments for drug evaluations. Over the last decade, evidence-based assessment 
of food and nutritional products has accelerated. Specific quantitative tools to syn-
thetize evidence have been increasingly developed, and used for decision support. 
This work aims at highlighting the critical role of systematic reviews and model-based 
evidence synthesis in the field of food sciences and nutrition, especially with the view 
of safety assessment. To first set the scene of food assessment in Europe, the latest 
Guidelines on Systematic Reviews published by the European Food Safety Authority 
(EFSA) (EFSA, 2010) are described with the approach on how to handle observational 
